研发新进展：对抗HIV的新抗体有新的突破

<p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">近期，上海酶联生物报导：对立</font>HIV<font face="宋体">的新抗体有望打破！</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><strong><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">ELISA<font face="宋体">试剂盒</font></span></strong><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">研讨人员标明，能发生很多中和抗体（</font><font face="Calibri">bNAbs</font><font face="宋体">）的艾滋病</font><font face="Calibri">HIV</font><font face="宋体">携带者比那些不能发生此类抗体的人，有不同的免疫活化系统。中和抗体是一种有助于按捺艾滋病</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">b<font face="宋体">毒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">的抗体，但是</font>bNAbs <font face="宋体">不能彻底的清除艾滋病患者体内的</font><font face="Calibri">HIV</font><font face="宋体">传染源，但科学家以为一个成功的防备</font><font face="Calibri">HIV</font><font face="宋体">的疫苗有必要能诱导</font><font face="Calibri">bNAbs</font><font face="宋体">。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">新的研讨标明，</font>bNAbs<font face="宋体">的生成可能与特定个别免疫功用的改变有关，这种免疫功用可能不是受</font><font face="Calibri">HIV</font><font face="宋体">感染而发生。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">界说怎么安全的仿制这些不是经</font>HIV<font face="宋体">感染而发生的疫苗受体，能更好的指导规划实验取得防备艾滋病的疫苗。这项研讨由国家过敏症和流行症研讨所（</font><font face="Calibri">NIAID</font><font face="宋体">）资助支撑，</font><font face="Calibri">NIAID</font><font face="宋体">是美国国立卫生研讨院的一部分。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">杜克大学的研讨人员领导的一个团队，经过搜集</font>HIV<font face="宋体">携带者的血样并加以研讨，发现出了这种免疫改变。该团队将</font><font face="Calibri">51</font><font face="宋体">个含很多</font><font face="Calibri">bNAbs</font><font face="宋体">个别的血样同</font><font face="Calibri">51</font><font face="宋体">个不含或含很少</font><font face="Calibri">bNAbs</font><font face="宋体">的个别血样作了比较，分析结果标明，许多由慢性</font><font face="Calibri">HIV</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">b<font face="宋体">毒</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">感染引发的免疫细胞功用的改变与高水平的</font>bNAbs<font face="宋体">相关联。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">免疫功用的特定改变包含：高频率的攻击本身细胞的抗体</font>&mdash;&mdash;本身抗体、少量免疫调理性<font face="Calibri">T</font><font face="宋体">细胞&mdash;&mdash;在这些个别中也很少被激活、高频率的回忆</font><font face="Calibri">T</font><font face="宋体">卵泡辅佐细胞。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><font face="宋体">在这种免疫系统结构下，能发生抗体的免疫细胞</font>&mdash;&mdash;<font face="Calibri">B</font><font face="宋体">细胞的活性可能不受按捺，由于该免疫系统支撑</font><font face="Calibri">T</font><font face="宋体">卵泡辅佐细胞，也可能被调理性</font><font face="Calibri">T</font><font face="宋体">细胞阻止。反之，这可能导致</font><font face="Calibri">bNAbs</font><font face="宋体">更有用的生成来对立</font><font face="Calibri">HIV</font><font face="宋体">。这些发现为研发能改善个别免疫系统的</font><font face="Calibri">HIV</font><font face="宋体">疫苗供给了一个捷径。</font></span><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p> <p class="MsoNormal"><span style="mso-spacerun:'yes';font-family:宋体;mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;">重视上海酶联生物科技，我司为您供给后续动态，关于抗体产品，我司供给技术支撑。欢迎来电咨询。</span><span style="mso-spacerun:'yes';font-family:Calibri;mso-fareast-font-family:宋体;mso-bidi-font-family:'Times New Roman';font-size:9.0000pt;mso-font-kerning:1.0000pt;"><o:p></o:p></span></p>